This inventor holds 1 USPTO granted patent. Top assignee: Genzyme Corporation. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Maria Carmen Obinu: Innovator in Neurodegenerative Treatments
Introduction
Maria Carmen Obinu is a prominent inventor based in Paris, France. She has made significant contributions to the field of neurodegenerative diseases through her innovative research and patenting efforts. Her work focuses on developing RNA interference (RNAi) technologies aimed at treating conditions such as Parkinson's disease.
Latest Patents
Maria Carmen Obinu holds a patent for her invention titled "Variant RNAi against alpha-synuclein." This patent includes RNAi molecules designed to treat neurodegenerative synucleinopathies. The RNAi molecules specifically target the expression of alpha-synuclein (SNCA). Additionally, her patent encompasses expression constructs, vectors (such as rAAV), cells, viral particles, and pharmaceutical compositions that utilize the RNAi technology. The methods and kits related to this RNAi are intended for treating various neurodegenerative conditions, including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. She has 1 patent to her name.
Career Highlights
Maria Carmen Obinu is associated with Genzyme Corporation, where she continues to advance her research in neurodegenerative diseases. Her work has garnered attention for its potential impact on treatment options for patients suffering from these debilitating conditions.
Collaborations
Some of her notable coworkers include Bradford Elmer and Brenda Richards, who contribute to her research endeavors and collaborative projects.
Conclusion
Maria Carmen Obinu is a trailblazer in the field of neurodegenerative disease research, with her innovative RNAi technology paving the way for new treatment possibilities. Her contributions are vital in the ongoing fight against these challenging conditions.